Skip to main content
Literatur
1.
Zurück zum Zitat Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E (2009) RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs 18:1085–1102CrossRefPubMed Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E (2009) RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs 18:1085–1102CrossRefPubMed
2.
Zurück zum Zitat Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K (2009) Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Expert Rev Anticancer Ther 9:1125–1134CrossRefPubMed Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K (2009) Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Expert Rev Anticancer Ther 9:1125–1134CrossRefPubMed
3.
Zurück zum Zitat Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, Terpos E (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41:721–729CrossRefPubMed Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, Terpos E (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41:721–729CrossRefPubMed
4.
Zurück zum Zitat Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166–1172CrossRefPubMed Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166–1172CrossRefPubMed
7.
Zurück zum Zitat Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, Wang J, Jun S, Yeh H, Dansey R (2009) A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15—34th ESMO Multidisciplinary Congress—Proffered Paper sessions 7(3):12 Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, Wang J, Jun S, Yeh H, Dansey R (2009) A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15—34th ESMO Multidisciplinary Congress—Proffered Paper sessions 7(3):12
8.
Zurück zum Zitat Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, Fan M, Braun A, Dansey R, Jun S (2009) Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15—34th ESMO Multidisciplinary Congress—Presidential session II 7(3):2–3 Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, Fan M, Braun A, Dansey R, Jun S (2009) Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15—34th ESMO Multidisciplinary Congress—Presidential session II 7(3):2–3
9.
Zurück zum Zitat Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C, Boukovinas I, Koloutsos G, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362CrossRefPubMed Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C, Boukovinas I, Koloutsos G, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362CrossRefPubMed
10.
Zurück zum Zitat Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS (2008) Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121(475–483):e473 Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS (2008) Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121(475–483):e473
12.
Zurück zum Zitat Kyrgidis A, Vahtsevanos K (2009) "Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws. Clin Oral Investig 13:479–480CrossRefPubMed Kyrgidis A, Vahtsevanos K (2009) "Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws. Clin Oral Investig 13:479–480CrossRefPubMed
Metadaten
Titel
Denosumab-related osteonecrosis of the jaws
verfasst von
A. Kyrgidis
K. A. Toulis
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 1/2011
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1177-6

Weitere Artikel der Ausgabe 1/2011

Osteoporosis International 1/2011 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.